Back

LOI deadline: Tuesday, September 1, 2020

Thank you for your submission.

Thank you for submitting your Letter of Intent for the SU2C Health Equity Breakthrough Team Research Grant Program. Teams selected as finalists will be invited on or before Thursday, October 1, 2020, to submit a full application and to attend the in-person Selection Meeting. The deadline for the full application is Friday, January 8, 2021, at 12:00pm noon Eastern Daylight Time. The in-person selection meeting will be held on Friday, January 22, 2021, in Los Angeles, CA. The selected team will be notified mid-February 2021 with anticipated project start dates in May 2021. Please contact proposals@su2c.org if you have any questions.

Sorry!

There are errors in the form.

Required Fields*

Primary Scientist

First name is required
Last name is required
Degree is required
Institution is required
A valid email address is required
Please enter a valid phone number
Mailing Address is required
Please enter a valid city name
Please enter a valid state/province
Country is required
Please enter a valid zip/postal code

Applicant's Assistant

First name is required
Last name is required
A valid email address is required
Please enter a valid phone number
Please upload your CV as a text (.txt) file
Add Co-Applicant (optional, up to two)

Please upload your Letter of Intent as a text (.txt) file

SU2C HEALTH EQUITY BREAKTHROUGH TEAM RESEARCH GRANT PROGRAM REQUEST FOR APPLICATIONS

Applications Requested for Stand Up To Cancer (SU2C) Health Equity Breakthrough Team Research Grant Program

Request for Applications: Stand Up To Cancer (SU2C) invites applications for the SU2C Health Equity Breakthrough Team Research Grant Program. The Breakthrough Team represents an unprecedented opportunity to bring together the best scientific minds from diverse fields of research to concentrate on new approaches to address health disparities in the context of cancer research. The goal of SU2C “health equity” is for patients of all racial and ethnic backgrounds or hard to reach locations to equally benefit from breakthroughs in cancer treatments; and for cancer research to address remediable differences, i.e., genetics, biology, risks, incidence, and mortality, and barriers to participation in research, in order to attain comparable outcomes for all racial and ethnic populations. The Breakthrough Team will be unique in bringing together key stakeholders that are deeply connected to the impacted communities, integrating social/behavioral determinants of health and outreach with cancer biology, prevention, and treatment, and realizing the ideal of health equity. Applicants will identify barriers, address prevalence in a particular population, share planned outreach, and provide evidence of previous successes in the patient population(s). Projects may focus on particular organ sites or blood cancers, molecular pathways of cancer, patient populations, or innovative approaches to research. They are designed to accelerate the application of new preventive, diagnostic, or therapeutic approaches in the clinic or community that lead to patient involvement and outcomes within the first two to three years of the grant funding period. Proposed ideas should be based on perceived opportunities for success as well as high-priority areas reflecting critical patient needs. The Breakthrough Team efforts will include mentorship and development for the next generation of investigators. The Breakthrough Team is supported by a transformational grant from Genentech, a member of the Roche Group.

Applications: The application includes a text application template and spreadsheet templates for completion and submission. The spreadsheet templates include: (1) Milestones and Deliverables Timeline, (2) Requested funding and required regulatory approvals per Specific Aim as Clinical Trials, (3) Budget per year and per Institution, and (4) Personnel Tracker. Collaborative groups of researchers from diverse institutions and diverse research disciplines are preferred, and all applications must include inter-institutional collaborations. Applicants are encouraged to include a community based practice. Curriculum vitae (NIH Biosketch preferred but not required) with a recent (five year) publication list, as well as current funding, should be included for Team Leadership (Team Leader, Team Co-Leader, and Team Principal Investigators). Teams are required to have a Team Leader and a Team Co-Leader. There are no citizenship or residency status restrictions for team members. Teams must include a Project Manager and at least two Patient Advocates. Projects should be planned for four years, with any proposed trials completing accrual by the end of the grant period. The scale of a project should not exceed US $6 million total. Letters of Support from leadership at each institution and company involved with the Team are required. If a clinical trial is proposed, then a clinical trial protocol or a compelling justification for delaying the protocol development will be required. The Letter of Intent (LOI) deadline is Friday, September 1, 2020, at 12:00pm noon Eastern Daylight Time.

Notification. Teams selected as finalists will be invited to submit a full application on or before Thursday, October 1, 2020. The deadline for the full application is Friday, January 8, 2021, at 12:00pm noon Eastern Daylight Time. The Team Leader and Co-Leader of finalist teams will be required to present the proposal at an in-person selection meeting to be held on Wednesday, January 27, 2021, in Los Angeles, CA. The selected team will be notified mid-February 2021 with anticipated project start dates in May 2021.

If you have questions, please contact proposals@su2c.org.

See this video for viewing more information about this program.

Download Program Guidelines and Application Instructions
Download
Download Letter of Intent Template
Download